CD226 and neoplasm: TIGIT binds to its ligand PVR or CD155 on the tumour cells with a much higher affinity than its activating counterpart CD226 (DNAM-1), thereby inhibiting the interaction between CD226 and CD155 which is widely expressed on tumour cells (158–160, 164).